Fürst R, Vollmar A M
Institute of Pharmaceutical Biology, Biocenter, Goethe-University, Frankfurt am Main, Germany.
Pharmazie. 2013 Jul;68(7):478-83.
Microtubule-targeting agents (MTAs) are the most frequently used anti-cancer drugs. They can be divided into tubulin stabilizing and destabilizing agents. Their mode of action has been ascribed to their ability to interfere with the spindle apparatus and, thus, to block mitosis leading to tumor cell death. However, this view has been challenged in the last years and it became increasingly evident that non-mitotic actions of MTAs, i.e. their ability to affect the dynamics of interphase microtubules, are the most relevant mechanism underlying their efficacy. In this review we are presenting a distinct selection of examples of studies describing biological effects of MTAs in three areas: (i) mitosis-independent cell death and metastasis, (ii) tumor angiogenesis, and (iii) vascular-disrupting activity.
微管靶向药物（MTAs）是最常用的抗癌药物。它们可分为微管蛋白稳定剂和微管蛋白解聚剂。其作用方式归因于它们干扰纺锤体装置的能力，从而阻断有丝分裂导致肿瘤细胞死亡。然而，这种观点在过去几年中受到了挑战，越来越明显的是，MTAs的非有丝分裂作用，即它们影响间期微管动力学的能力，是其疗效的最相关机制。在本综述中，我们展示了一系列不同的研究实例，这些研究描述了MTAs在三个领域的生物学效应：（i）非有丝分裂依赖性细胞死亡和转移，（ii）肿瘤血管生成，以及（iii）血管破坏活性。
